Prospective longitudinal multi-omics study of palbociclib resistance in hormone receptor+/HER2-metastatic breast cancer.

被引：5
|
作者：
Park, Yeon Hee
Im, Seock-Ah
Park, Kyunghee
Wen, Ji
Min, Ahrum
Bonato, Vinicius
Park, Seri
Ram, Sripad
Lee, Dae-Won
Kim, Ji-Yeon
Lee, Kyung-Hun
Lee, Won-Chul
Lee, Jisook
Kim, Hyunseon
Lee, Won-Woo
Choi, Yoon-La
Weinrich, Scott
Ryu, Han Suk
Park, Woong-Yang
Kan, Zhengyan
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Canc Res Inst, Coll Med, Seoul, South Korea
[3] Samsung Genome Inst, Samsung Med Ctr, Seoul, South Korea
[4] Pfizer, Oncol Res & Dev, San Diego, CA USA
[5] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst, Seoul, South Korea
[6] Pfizer, Biostat, San Diego, CA USA
[7] SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea
[8] Pfizer, Drug Safety R&D, San Diego, CA USA
[9] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
[10] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[11] Seoul Natl Univ Hosp, Seoul, South Korea
[12] Pfizer, Seoul, South Korea
[13] Sungkyunkwan Univ, Dept Pathol & Translat Genom, Samsung Med Ctr, Sch Med, Seoul, South Korea
[14] Pfizer Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.1013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1013
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
    Yeon Hee Park
    Seock-Ah Im
    Kyunghee Park
    Ji Wen
    Kyung-Hun Lee
    Yoon-La Choi
    Won-Chul Lee
    Ahrum Min
    Vinicius Bonato
    Seri Park
    Sripad Ram
    Dae-Won Lee
    Ji-Yeon Kim
    Su Kyeong Lee
    Won-Woo Lee
    Jisook Lee
    Miso Kim
    Hyun Seon Kim
    Scott L. Weinrich
    Han Suk Ryu
    Tae Yong Kim
    Stephen Dann
    Yu-Jin Kim
    Diane R. Fernandez
    Jiwon Koh
    Shuoguo Wang
    Song Yi Park
    Shibing Deng
    Eric Powell
    Rupesh Kanchi Ravi
    Jadwiga Bienkowska
    Paul A. Rejto
    Woong-Yang Park
    Zhengyan Kan
    [J]. Genome Medicine, 15
  • [2] Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
    Park, Yeon Hee
    Im, Seock-Ah
    Park, Kyunghee
    Wen, Ji
    Lee, Kyung-Hun
    Choi, Yoon-La
    Lee, Won-Chul
    Min, Ahrum
    Bonato, Vinicius
    Park, Seri
    Ram, Sripad
    Lee, Dae-Won
    Kim, Ji-Yeon
    Lee, Su Kyeong
    Lee, Won-Woo
    Lee, Jisook
    Kim, Miso
    Kim, Hyun Seon
    Weinrich, Scott L.
    Ryu, Han Suk
    Kim, Tae Yong
    Dann, Stephen
    Kim, Yu-Jin
    Fernandez, Diane R.
    Koh, Jiwon
    Wang, Shuoguo
    Park, Song Yi
    Deng, Shibing
    Powell, Eric
    Ravi, Rupesh Kanchi
    Bienkowska, Jadwiga
    Rejto, Paul A.
    Park, Woong-Yang
    Kan, Zhengyan
    [J]. GENOME MEDICINE, 2023, 15 (01)
  • [3] registHER: A prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer.
    Tanchiu, E
    Kaufman, PA
    Paik, S
    Ulcickas-Yood, M
    Mayer, M
    Tripathy, D
    Rugo, H
    Brufsky, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 46S - 46S
  • [4] Real world experience of palbociclib in hormone receptor-positive metastatic breast cancer.
    Malik, Faizan
    Ali, Naveed
    Jafri, Syed Imran Mustafa
    Sundermeyer, Mark L.
    Seidman, Michael Jeffrey
    Fidler, Christian Joseph
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer
    Guerrero-Zotano, Angel
    Belli, Stefania
    Zielinski, Christoph
    Gil-Gil, Miguel
    Fernandez-Serra, Antonio
    Ruiz-Borrego, Manuel
    Gil, Eva Maria Ciruelos
    Pascual, Javier
    Munoz-Mateu, Montserrat
    Bermejo, Begon
    Vila, Mireia Margeli
    Anton, Antonio
    Murillo, Laura
    Nissenbaum, Bella
    Liu, Yuan
    Herranz, Jesus
    Fernandez-Garcia, Daniel
    Caballero, Rosalia
    Lopez-Guerrero, Jose Antonio
    Bianco, Roberto
    Formisano, Luigi
    Turner, Nicholas
    Martin, Miguel
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1557 - 1568
  • [6] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    [J]. FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [7] A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC).
    Wander, Seth Andrew
    Zangardi, Mark
    Niemierko, Andrzej
    Kambadakone, Avinash
    Kim, Leslie S. L.
    Xi, Jing
    Pandey, Apurva Kumari
    Spring, Laura
    Stein, Casey
    Juric, Dejan
    Kuter, Irene
    Moy, Beverly
    Mulvey, Therese Marie
    Vidula, Neelima
    Isakoff, Steven J.
    Yuen, Megan
    Brufsky, Adam
    Ma, Cynthia X.
    O'Shaughnessy, Joyce
    Bardia, Aditya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.
    Engel-Nitz, Nicole M.
    Becker, Laura
    Gerdes, Randall
    Hao, Yanni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] The mutational profile of ER-, PR+, HER2-metastatic breast cancer.
    Fischbach, Neal A.
    Huang, Richard S. P.
    Lustberg, Maryam B.
    Pelletier, Maureen
    Pusztai, Lajos
    Sivakumar, Smruthy
    Sokol, Ethan
    Ross, Jeffrey S.
    Levy, Mia Alyce
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Multi-omics fusion analysis models with machine learning predict survival of HER2-negative metastatic breast cancer: a multicenter prospective observational study
    Wang Jiani
    Liu Yuwei
    Zhang Renzhi
    Liu Zhenyu
    Yi Zongbi
    Guan Xiuwen
    Zhao Xinming
    Jiang Jingying
    Tian Jie
    Ma Fei
    [J]. 中华医学杂志(英文版), 2023, 136 (07)
12345